Despite the absence of a robust biomarker that accurately predicts immunotherapy response, evidence suggests a strong correlation between immunotherapy treatment response and PD-L1 levels in certain cancer types, particularly lung cancers [22,23]. This evidence concerns the gene CD274 and lung carcinoma.